The role of orexin in NT1

NT1 is associated with a loss of orexin1,2

Orexin is a neuropeptide that helps regulate the “switch” between sleep and wake states3

A loss of orexin destabilizes the switch between sleep and wake states3,4

  • In NT1, orexin is diminished and the sleep-wake cycle is dysregulated, causing abrupt transitions between wake and sleep across a 24-hour period3,4
  • A loss of orexin signaling results in dysregulation of downstream activity in the brain, which can contribute to a range of NT1 symptoms4,6

NT1 is a chronic neurological disorder;
symptoms affect patients day and night7

The hallmark symptoms of NT1 are sometimes referred to as the pentad7 

Excessive daytime 
sleepiness (EDS) 

A tired person in the daytime icon

Cataplexy

A person with sudden loss of muscle control icon

Disrupted nighttime sleep

A person with disrupted nighttime sleep icon

Hypnagogic/hypnopompic hallucinations

A cloud over a person’s head depicting hallucinations icon

Sleep paralysis

A person with sleep paralysis lying in bed icon

Scope and severity of NT1 symptoms can vary among individuals.

NT1 symptoms can impact patients’ quality of life and daily functioning8-10

A majority of patients across multiple surveys reported that symptoms can impact:

Socializing and interacting with family and friends8-10,*†‡

Two people having a conversation at a table icon

Work or school performance8,10,*‡

A person sitting at a desk using a desktop computer and a clock is on the wall icon

Sex life and relationships9,†

Two people with their arms around each other icon
A woman holding a smartphone

Meet Olivia

Meet Olivia

35 YEARS OLD
Diagnosed with NT1

35 YEARS OLD
Diagnosed with NT1

TREATMENT CONSIDERATIONS

  • Olivia is currently on treatment and has tried several treatments to manage her NT1
  • She has previously tried a wake-promoting therapy during the day and a sleep-inducing therapy at night
  • She is experiencing EDS and cataplexy during the day, along with the broader symptoms of NT1
  • She is concerned that her NT1 symptoms could be affecting her job
  • Olivia made an appointment with her sleep specialist to discuss her concerns

TREATMENT CONSIDERATIONS

  • Olivia is currently on treatment and has tried several treatments to manage her NT1
  • She has previously tried a wake-promoting therapy during the day and a sleep-inducing therapy at night
  • She is experiencing EDS and cataplexy during the day, along with the broader symptoms of NT1
  • She is concerned that her NT1 symptoms could be affecting her job
  • Olivia made an appointment with her sleep specialist to discuss her concerns

Actor portrayal. Hypothetical patient profile.

Individual results may vary.

Medication may not be appropriate for all patients.

GABA=gamma-aminobutyric acid; NT1=narcolepsy type 1; NT2=narcolepsy type 2.

References: 1. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83-93. doi:10.1038/s41583-018-0097-x 2. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662. doi:10.1056/NEJMra1500587 3. De Luca R, Nardone S, Grace KP, et al. Orexin neurons inhibit sleep to promote arousal. Nat Commun. 2022;13(1):4163. doi:10.1038/s41467-022-31591-y 4. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171-181. doi:10.1038/nrn2092 5. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev. 2012;92(3):1087-1187. doi:10.1152/physrev.00032.2011 6. Toor B, Ray LB, Pozzobon A, Fogel SM. Sleep, orexin and cognition. Front Neurol Neurosci. 2021;45:38-51. doi:10.1159/000514960 7. Morse AM, Kim SY, Harris S, Gow M. Narcolepsy: beyond the classic pentad. CNS Drugs. 2025;39(suppl 1):S9-S22. doi:10.1007/s40263-024-01141-9 8. Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419-425. doi:10.5664/jcsm.6494 9. Davidson RD, Biddle K, Nassan M, Scammell TE, Zhou ES. The impact of narcolepsy on social relationships in young adults. J Clin Sleep Med. 2022;18(12):2751-2761. doi:10.5664/jcsm.10212 10. Ortiz LE, Morse AM, Krahn L, et al. A survey of people living with narcolepsy in the USA: path to diagnosis, quality of life, and treatment landscape from the patient's perspective. CNS Drugs. 2025;39(suppl 1):S23-S36. doi:10.1007/s40263-024-01142-8 11. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals.